CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia by Cuesta-Mateos, Carlo et al.
RAPID COMMUNICATION Open Access
CCR7 as a novel therapeutic target in t-cell
PROLYMPHOCYTIC leukemia
Carlos Cuesta-Mateos1,2*† , Patricia Fuentes3†, Alexandra Schrader4†, Raquel Juárez-Sánchez1,2, Javier Loscertales5,
Tamara Mateu-Albero1, Lorena Vega-Piris6, Marina Espartero-Santos1, Ana Marcos-Jimenez1,
Blanca Andrea Sánchez-López1, Yaiza Pérez-García1, Dennis Jungherz4, Sebastian Oberbeck4, Linus Wahnschaffe4,
Anna Kreutzman1, Emma I. Andersson7, Satu Mustjoki7,8, Edgar Faber9, Ana Urzainqui1, Manuel Fresno10,
Kostantino Stamatakis10, Arantzazu Alfranca1, Fernando Terrón2, Marco Herling4, María Luisa Toribio3 and
Cecilia Muñoz-Calleja1,11
Abstract
T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies.
Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all
patients relapse. Therefore, there is an unmet medical need for novel therapies in T-PLL. As the chemokine receptor
CCR7 is a molecule expressed in a wide range of malignancies and relevant in many tumor processes, the present
study addressed the biologic role of this receptor in T-PLL. Furthermore, we elucidated the mechanisms of action
mediated by an anti-CCR7 monoclonal antibody (mAb) and evaluated whether its anti-tumor activity would warrant
development towards clinical applications in T-PLL. Our results demonstrate that CCR7 is a prognostic biomarker for
overall survival in T-PLL patients and a functional receptor involved in the migration, invasion, and survival of
leukemic cells. Targeting CCR7 with a mAb inhibited ligand-mediated signaling pathways and induced tumor cell
killing in primary samples. In addition, directing antibodies against CCR7 was highly effective in T-cell leukemia
xenograft models. Together, these findings make CCR7 an attractive molecule for novel mAb-based therapeutic
applications in T-PLL, a disease where recent drug screen efforts and studies addressing new compounds have
focused on chemotherapy or small molecules.
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Background
T-cell prolymphocytic leukemia (T-PLL) is a rare
hematological malignancy, which represents ~ 2% of all
mature lymphocytic leukemia in adults [1, 2]. T-PLL is
characterized by a rapid proliferation of mature post-
thymic prolymphocytes [1, 3, 4] and the presence of
cytogenetic abnormalities affecting the chromosomes
14q32 and Xq28 that lead to over-expression and activa-
tion of the TCL1 and MTCP1 oncogenes, respectively [5–
7]. In addition, T-PLL is featured by an aggressive clinical
course and by poor responses to alkylating chemother-
apies [1, 4, 8, 9]. Therapeutic options for T-PLL have
broadened with the advent of purine analogs [10], and
particularly by the anti-CD52 monoclonal antibody (mAb)
alemtuzumab [11, 12]. With these options, response rates
exceed 90% and the median overall survival (OS) was ex-
tended from ~ 7.5 to ~ 20months following alemtuzumab
monotherapy or in combination with purine analogs [8,
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10, 13–15]. Nevertheless, the relapse rate after these
agents is ~ 100% with a median duration of remissions of
~ 12months. Only 10–15% of patients experience long-
term (> 5 years) survival [8, 13, 16, 17] after consolidation
with allogeneic hematopoietic stem cell transplantation
(allo-HSCT) [16, 18]. Given these unsustained responses
after induction and the limited eligibility for a consolidat-
ing allo-HSCT, there is an urgent clinical need for more
efficient and profound tumor cell clearance in T-PLL.
To overcome the restricted availability of active therap-
ies in T-PLL, we focused on the homeostatic chemokine
receptor CCR7 as a targetable structure. CCR7 controls
the entry of normal naïve (TN) and central memory T-
cells (TCM) into the secondary lymphoid organs (SLO).
CCR7 is expressed in mature T-cell malignancies, such as
adult T-cell leukemia/lymphoma (ATLL) [19] and Sézary
syndrome (SS) [20], and enables the entry of acute
lymphoblastic leukemia (ALL) cells to the central nervous
system (CNS) where CCR7 promotes survival and prolif-
eration [21, 22]. In the present work, we studied the ex-
pression and functions of CCR7 in primary samples of T-
PLL and evaluated in vitro and in vivo its potential as a
therapeutic target for a mAb-based therapy.
Methods
Samples
T-PLL patients included in this study were diagnosed ac-
cording to WHO and refined consensus criteria [2, 3].
Informed consent was obtained in each contributing
center in accordance with the Declaration of Helsinki.
Experimental procedures were approved by the Institu-
tional Board of the Hospital de La Princesa. Cells isola-
tion from freshly donated peripheral blood (PB) was
done using Ficoll-paque plus density gradient centrifuga-
tion (Amersham Biosciences, Little Chalfont, UK). Cells
were cultured in RPMI-1640 media supplemented with
10% heat-inactivated fetal bovine serum (FBS), 2 mM L-
glutamine and 100 U/mL penicillin/100 μg/mL strepto-
mycin at 37 °C in 5% CO2. Peripheral blood mono-
nuclear cells (PBMCs) from healthy donors (HD) were
obtained from PB or blood buffy coats. Human umbilical
vein endothelial cells (HUVEC) were isolated from
freshly donated umbilical cords in accordance to the
Declaration of Helsinki.
Cell lines
The human cell line SUP-T11 was purchased from the
DSMZ German collection of microorganisms and cell
cultures (Braunschweig, Germany). Identity was con-
firmed using multiplex PCR of minisatellite markers per-
formed by DSMZ. Cells were cultured according to
supplier’s protocols. Absence of Mycoplasma contamin-
ation was routinely tested for with MYCOPLASMA Gel
Form kit (Biotools, Madrid, Spain).
Reagents
The antibody alemtuzumab was provided by Genzyme
(Cambridge, MA). Mouse anti-hCCR7 mAb (150503
clone, IgG2a) and the respective isotype control (IC) were
obtained from R&D Systems (Minneapolis, MN). The
anti-CCR7 mAb was selected owed to its reported ability
to block CCR7-ligand interactions and killing target cells
[22–25]. In a confirmatory assay, clone 150503 showed no
agonistic effects in β-arrestin recruitment assays whereas
CCL21 triggered a strong activation (Supplementary
Figure 1-A). Similarly, we confirmed that the selected
clone did not induce internalization processes upon bind-
ing to surface CCR7 (Supplementary Figure 1-B).
Flow cytometry
Expression levels of CCR7, CD52, and CCR4 on T-PLL
cells were determined using PE (phycoerythrin)- or PE-
cy5.5-conjugated anti-CCR7 (clone 150503, R&D Sys-
tems, Minneapolis, MN), PE-conjugated anti-CD52 or
PE-conjugated anti-CCR4 (clones 4C8 and 1G1, respect-
ively, BD Biosciences, San Jose, CA), with auxiliary CD5-
FITC (clone UCHT2), CD7-APC (clone M-7 T01), and
CD3-APC-H7 (clone SK7) (all from BD Biosciences). In
all cases, an appropriate fluorochrome-conjugated IC
was included and 104 neoplastic T-cells were acquired.
Immunofluorescence staining was analyzed on a FACS
Canto II flow cytometer (BD Biosciences) using Infinicyt
v.1.3.0 (Cytognos, Salamanca, Spain) and Diva v.2.4 (BD
Biosciences) software. Results are presented as the per-
centage of CCR7 positive cells and the median fluores-
cence intensity (MFI) of CCR7, CD52, and CCR4
expression relative to the IC (RMFI). For determination
of CCR7 expression on TN or TCM, we used a flow cy-
tometry panel containing the following antibodies: CCR7
PE (R&D), and CD45RA-PerCP-Cy5.5, CD45RO-FITC,
CD3-V500, CD4-V450, CD27-APC (all from BD
Biosciences).
Western blot
Cells were serum-starved for 4 h, incubated with anti-CCR7
mAb (10 μg/mL) or the appropriate IC, treated with hCCL19
or hCCL21 (1 μg/mL, PeproTech, Rocky Hills, NJ) for the in-
dicated times and then lysed in ice-cold modified-RIPA buf-
fer. Equal amounts of protein were analyzed by SDS-PAGE
and immunoblotting using phospho-ERK1/2 (Thr202/
Tyr204), phospho-AKT (Ser473), phospho-MLC (Ser-19),
anti-AKT, anti-ERK1/2 and anti-MLC specific antibodies, all
of them purchased from Cell Signaling Technology (Danvers,
MA). Membranes were first probed with antibodies against
the phospho-proteins under study, and then re-probed with
antibodies recognizing the total amount of each protein.
Bands were visualized using enhanced chemiluminescence
(Amersham Pharmacia Biotech, Buckinghamshire UK), and
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quantified with a LAS1000 image analyzer (FujiFilm, Tokyo,
Japan).
Migration
Chemotaxis of T-PLL cells was assayed in Transwell
chambers (6.5 mm diameter, 10 μm thickness and 5 μm
diameter pore size, Corning-Costar, Tewksbury, MA) as
previously described [23]. Only samples from patients
with > 95% of tumor cells were analyzed. Briefly, 5 × 105
cells suspended in RPMI-1640, 0.5% BSA were loaded in
the upper chamber and chemokines (1 μg/mL) were
added to the lower compartment. Migration was allowed
to proceed for 4 h at 37 °C and 5% CO2. When required,
cells were pre-incubated for 30 min with anti-CCR7
mAb (10 μg/mL) or an IC, which were maintained
throughout the chemotaxis assays. Cells that migrated to
the lower chamber were stained with anti-CD3-PE mAb
(clone SK7, BD Biosciences) and anti-CD7-APC (clone
M-7 T01, BD Biosciences), enumerated by flow cytome-
try using a FACS Canto II flow cytometer and compared
with the number of cells loaded in the upper chamber.
The percentage of migrated cells (% of input) was calcu-
lated according to the following formula: 100 x (number
of cells in the lower chamber / number of cells loaded in
the upper chamber).
Invasion
Three million serum-starved T-PLL cells were harvested
and included in 4 °C liquid Matrigel™ (BD Biosciences
Pharmingen, San Diego, CA). Then, the Matrigel sus-
pension containing cells was added to the Transwell
chambers (Costar) and incubated at 37 °C for 30 min.
Cells were incubated with anti-CCR7 mAb (10 μg/mL)
or IC prior to addition of Matrigel. Once Matrigel was
solidified the chemokines were added to the lower
chamber and cells were allowed to migrate in RPMI-
1640 with 1% FBS for 24 h at 37 °C in 5% CO2 atmos-
phere. Cells that had migrated to the lower chamber
were quantified as described in migration assays.
Transendothelial migration (TEM)
Tumor cell transmigration through intact endothelium
was examined using monolayers of cultured human um-
bilical vein endothelial cells (HUVEC) seeded in
gelatine-coated Transwell chambers (Costar) at a density
of 4 × 104 cells per well as previously reported [24]. The
integrity of HUVEC monolayers was confirmed by tolui-
din blue staining and confluent monolayers were stimu-
lated with 15 ng/mL recombinant TNF-α (R&D
Systems), for 16 h prior to the assay. Before applying to
upper chambers, T-PLL cells were incubated with anti-
CCR7 mAb (10 μg/mL) or an IC. Then, leukemic cells
(5 × 105 per well) were suspended in medium with 1%
FBS, and placed into upper chambers. Lower chambers
were filled with medium containing hCCL19 or hCCl21
(1 μg/mL). After 4 h, cells in the lower chamber were re-
covered, stained and enumerated as described above.
Gelatin zymography
T-PLL cells (3 × 106) were placed in serum-free media
for 1 h and then treated with either IC or anti-CCR7
mAb (10 μg/mL) for 30 min. Cells were left untreated or
stimulated with CCL19 or CCL21 (1 μg/mL) for 24 h.
Conditioned media were collected and centrifuged to re-
move cells or debris. Samples were concentrated using a
Centricon (Millipore, Burlington, MA) to identical final
volumes for all conditions. Zymography was performed
on a 10% SDS-polyacrylamide gel incorporated with
0.1% gelatin (Sigma, San Luis, MO) [24]. FBS, containing
MMP-2 and MMP-9, was used as a positive control.
After electrophoresis, MMPs were allowed to re-nature
by washing the gel twice in 50mL of 2.5% Triton X-100
for 30 min, incubated for 24 h at 37 °C in developing buf-
fer (50 mM Tris pH 7.5, 200 mM NaCl, 10 mM CaCl2),
and stained for 1 h with 0.5% Coomassie brilliant blue
G250. After de-staining, gelatinolytic activity was visual-
ized as a transparent band against a blue background.
Analysis of proteolytic bands was performed using
LAS1000 image analyzer (FujiFilm).
Proliferation
T-PLL cells (5 × 105) were stained with 5 mM CellTrace™
Violet reagent (Molecular Probes, Eugene, OR) prior to
stimulation with CCL19 and CCL21 (1 μg/mL). Cell la-
belling was performed according to the manufacturer’s
protocol. Cells suspended in 1% FBS RPMI-1640
complete medium were then seeded in 96-well plates,
stimulated with chemokines and incubated for 7 days.
Every 24 h a total of 5 × 104 cells were analyzed on a
FACS CantoII BD with 405 nm excitation and a 450/40
band-pass emission filter in order to discriminate
discrete peaks representing successive generations of live
T-PLL cells. The growth rate was calculated according
to the formula: GR = [CellTrace™-positive-cells(t0) –
CellTrace™ -positive-cells (tX)] / CellTrace™ -positive-
cells(t0).
Cell survival
To examine whether CCR7 is involved in survival of T-
PLL, leukemic cells suspended in 1% FBS RPMI-1640
complete medium were seeded in 96-well plates at a
density of 106 cells/mL. Cells were either left untreated
or incubated for 30 min in the presence of anti-CCR7
mAb (10 μg/mL) before the addition of the ligands (1 μg
/mL). Cell viability was determined every 24 h by stain-
ing with the Annexin-V and the DNA dye 7-
aminoactinomycin-D (7-AAD) kit from BD Biosciences.
The apoptosis assay was used according to the
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manufacturer’s instructions to determine the percentage
of non-viable cells by flow cytometry.
Apoptosis
To assess whether anti-CCR7 mAb induces direct apop-
tosis, T-PLL cells were incubated with anti-CCR7 mAb
in RPMI-1640 complete medium. The cells were incu-
bated at 37 °C for a maximum of 72 h. Every 24 h
cells were stained with the Annexin-V/7-AAD assay
as described before. Then we carried out the quanti-
tative determination of the percentage of viable and
non-viable cells.
Complement-dependent cytotoxicity (CDC)
CDC assays were performed as previously described [25,
26]. Briefly, 2 × 105 T-PLL target cells were plated in a
96-well round-bottom plate together with the indicated
concentrations of purified anti-CCR7, alemtuzumab
(anti-CD52; Campath™, Genzyme, Cambridge, MA) or
IC antibodies. After 30 min at 37 °C the cells were
washed and complete RPMI-1640 medium containing
25% rabbit complement (Serotec-Bio-Rad, Hercules,
CA), with or without prior heat inactivation (56 °C, 30
min), was added. After 1.5 h, 7-AAD was used as a via-
bility exclusion dye and the percentage of non-viable
cells was measured by flow cytometry. The proportion
of specific lysis (% SL) was calculated with the formula:
% SL = 100 x (% dead cells with activated complement –
% dead cells with inactivated complement) / (100 – %
dead cells with inactivated complement).
Antibody-dependent cell-mediated cytotoxicity (ADCC)
ADCC assays were performed as previously described
[25, 26]. Cells were incubated with media alone or in the
presence of IC, alemtuzumab, or anti-CCR7 antibodies
(10 μg/mL) at 37 °C for 30 min. Unbound antibody was
washed off and the cells plated at 104 cells/well. Isolated
NK cells from healthy donors or wild-type mice were la-
beled with calcein-UV Cell Tracker (Invitrogen, Carls-
bad, CA) and stimulated with IL-2 (R&D Systems). NK
cells were used as effector cells at effector: target ratios
(E:T) of 6:1. After 4 h, cells were stained with 7AAD,
and analyzed by flow cytometry. The percentage of spe-
cific lysis was determined by: %SL = 100 × (ER-SR)/
(MR-SR). ER, SR, and MR represent experimental, spon-
taneous and maximum cell death. Data were normalized
to the media control.
In vivo studies
In vivo procedures were carried out at CBM-SO
(Madrid, Spain) in accordance with the guidelines ap-
proved by the Animal Experimentation Ethics Commit-
tee of the Spanish National Research Council. For the
in vivo proof-of-concept analyses, a novel systemic
xenograft model was developed by engrafting the human
t (14;14)-carrying T-cell leukemia line SUP-T11 into
sub-lethally irradiated (1.5 Gγ) immunodeficient mice.
To this end, 5 × 105 cells/mouse were intravenously (i.v.)
injected into 6–10 weeks-old RAG2−/−γc−/− [27] or
NOD.Cγ-Prkdcscid-IL2rgtm1Wjl/SzJ mice (NSG; The
Jackson Laboratory, Bar-Harbor, ME). Bioluminescent
models were performed by transducing SUP-T11 cells
with lentiviruses [28]. To measure luminescence, 150
mg/Kg of D-Luciferin was administrated intraperitone-
ally and tumor burden was monitored using the Xeno-
gen IVIS Lumina II imaging system (Caliper Life
Sciences, Waltham, MA). The photon flux emitted by
the luciferase-expressing cells is measured as an Average
radiance (photons/sec/cm2/sr). Imaging analysis is per-
formed using the Living Image™ Software 3.2 (Caliper
Life Sciences). Mice showing local tumor growth at the
injection site (and which developed no systemic disease
therefore) were discarded from analyses and sacrificed
for ethical reasons. Similarly, enrolled animals showing
endpoint weight loss or clinical signs were euthanized.
PB and organs [spleen, lymph node (LN), bone marrow
(BM), brain, lungs, and liver] were harvested in every
animal. From each organ collected, one half was mech-
anically disaggregated and conserved in PBS at 4 °C for
flow cytometry analyses. The percentage of tumor cells
was determined using specific (non cross-reacting with
murine cells) anti-hCD45-PerCP (clone 2D1) and anti-
hCD5-APC (clone L17F12) mAbs (all from BD Biosci-
ences). In some cases, the viability of tumor cells was
quantitatively determined by flow cytometry with the
Annexin-V-FITC/7-AAD assay on SUP-T11 cells. Simi-
larly, proliferation was determined by staining with anti-
Ki67-PE (BD Pharmingen). The distribution of leukemic
cells within the different organs was determined by im-
munohistochemistry (IHC) against hCD45. Briefly,
halves of organs and tissues extracted from mice were
fixed in 4% neutral buffered formaldehyde, paraffin-
embedded, and sliced in 4 μm sections. For human
CD45 inmmunohistochemistry, the antigen retrieval was
performed with tris-EDTA pH 9. Slides were stained
with 1:100 anti-hCD45 (clone 2B11&PD7/26, Cell
Marque, Rocklin, CA) by using the Dako REAL EnVision
Detection System (Dako, Glostrup, Denmark).
Statistics
Unless otherwise stated, quantitative variables are
expressed as measures of central tendency (mean) and
dispersion (SD, SEM). Quantitative variables with equal
variances (Levene’s test) were analyzed using t-test or
ANOVA. Mann-Whitney-U or Kruskal-Wallis tests were
used for heteroscedasticity. Survival curves were ana-
lyzed by the Kaplan-Meier method and log-rank test. A
Cox regression model was used to estimate cumulative
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risk for OS (hazard ratio, HR) vs proportion of CCR7+
T-PLL cells. Significance was set at values of < 0.05(*), <
0.01(**) or < 0.001(***).
Results
CCR7 is a functional receptor highly expressed on T-PLL
cells
B-cell malignancies with high levels of CCR7 show a
widespread nodular dissemination [29]. As T-PLL dis-
plays such an infiltration pattern, we asked whether
CCR7 levels were likewise augmented in this disease.
CCR7 surface expression was analyzed, at diagnosis, by
flow cytometry on malignant T-cells in peripheral blood
(PB) from 109 T-PLL patients, and on T-cells from 14
healthy donors. We found that CCR7 expression in
T-PLL lymphocytes was consistently higher than in
normal PB pan-T-cells [median of fluorescence inten-
sity relative to the control (RMFI) in T-PLL vs
healthy T-cells: 5.591 ± 0.7163 vs 1.094 ± 0.3021; Fig. 1
a]. Since surface chemokine receptor expression is
sensitive to several factor, we ruled out that CCR7
expression was not affected by antibody-induced in-
ternalization (Supplementary Figure 1), the anticoagu-
lant used, time from sample extraction to flow
cytometry tests, or isolation processes in fresh sam-
ples at diagnosis (data not shown). Also, a higher
proportion of CCR7-expressing cells was found in T-
PLL samples (T-PLL vs healthy T-cells: 75.95 ± 3.187
vs 39.76 ± 6.030, Fig. 1 b), where CCR7 expression
was found to be homogeneous whereas a bimodal dis-
tribution was seen in healthy PB pan-T-cells due to
the presence of CCR7-positive (TN, TCM) and CCR7-
negative subsets (effector cells) in a given sample
(Fig. 1c). To further characterize CCR7 expression we
also compared surface levels in our T-PLL cohort to
the expression in different non-tumor T-cell subsets
including CCR7-expressing TN and TCM cells (in both
CD3+CD4+ and CD3+CD8+ subsets). Results shown in
Fig. 1a,b,c reveal that there is no overall difference in
RMFI or in the proportion of CCR7-expressing cells
between T-PLL and normal CD4+ TCM cells. In
addition, a remarkable proportion of T-PLL cases
showed a CCR7 profile similar to a TN cell profile.
These results suggest that CCR7 expression in T-PLL
comprises a spectrum of differentiation ranging from
TN to TCM cell phenotypes. Accordingly, when we
studied the flow-cytometry based expression pattern
of CD45RO/CD45RA in our cohort, we could corrob-
orate that most cases resembled a memory phenotype
and that similar proportions of memory subsets were
found in CCR7-negative and CCR7-positive groups
(Table 1; RA+RO+: 33% in CCR7− vs 25% in CCR7+;
RA−RO+: 66% vs 67%).
Finally, CCR7 was functional in T-PLL cells and trig-
gered migration towards its cognate ligands, the chemo-
kines CCL19 and CCL21. CCR7 induced a bell-shape
dose-dependent migratory response with a maximum in-
duction by 1 μg/mL with both chemokines (Fig. 1d), a
concentration within the range estimated to exist in T-
zones of lymph nodes (LN) [30].
CCR7 expression is associated with shorter overall
survival of T-PLL patients
CCR7 expression on malignant cells is associated with
poor OS in solid tumors [31]. Nonetheless, such correl-
ation has not been described before in blood cancers. To
address this question, we dichotomized the uniformly
treated T-PLL patients (backbone of alemtuzumab in-
duction) of our cohort by setting a cut-off equal to the
20.5% of CCR7+ T-PLL cells as determined by ROC ana-
lysis (sensitivity of 84.55%; 95% CI: 76.93 to 90.44%).
This cut-off agreed with those of various cell makers
previously described [32].
Patients were then grouped into CCR7-positive [> 20%
positive cells; 83/96 (86.5%) patients] or CCR7-negative
[≤20%; 13/96 (13.5%)]. Accordingly, a density plot show-
ing the distribution of CCR7 positivity across all cases
clearly indicated that CCR7 expression was divided into
these two groups (Supplementary Figure 2) and pre-
cluded the use of a continuous expression of CCR7
in survival analyses. With these settings, the median
OS period was higher in CCR7-negative patients
(Fig. 1e: 38.23 vs 22,33 months; log-rank p = 0.0105;
HR = 0.4612; C.
I (95%) = 0.2549–0.8346). Four years after diagnosis,
44,8% of CCR7− patients survived whereas this propor-
tion decreased in the CCR7+ group to 26.65%; eight
years after diagnosis the proportions were 33% in CCR7−
patients vs 0% in CCR7+ patients. Fifteen cases in the
CCR7+ group and 4 in the CCR7− subset received an
allo-HSCT. To further study causality between expres-
sion of CCR7 and OS, Cox regression analyses were con-
ducted (Table 2). No association with OS was found
when we tested a continuous expression of CCR7, how-
ever, a HR of 2.426 (p = 0.044) was found for cases ex-
pressing CCR7 as compared to negative cases. Notably,
when risk analyses took into account only patients with
positivity for CCR7 (Table 2) no significant differences
in risk were found, indicating that all patients with ex-
pression of CCR7 had similar poor outcomes regardless
of the proportion of CCR7+ T-PLL cells at diagnosis.
CCR7 ligands trigger receptor signaling, a process
effectively blocked by CCR7 mAbs
The expression and functionality of CCR7 in T-PLL sug-
gested this molecule to be interrogated as a therapeutic
target in T-PLL. Given the lack of knowledge on the role
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Fig. 1 T-PLL cells express high levels of functional CCR7 that is associated with shorter overall survival (OS). a CCR7 relative median fluorescence
intensity (RMFI) in T-PLL cells compared to T-cells from healthy donors. T-cells obtained from PB samples of patients (n = 75) or healthy donors
(n = 10) were analyzed by flow cytometry to determine CCR7 surface density measured as MFI relative to a corresponding IC. b Proportion of
CCR7-positive T-cells is high in T-PLL. The percentage of CCR7-positive T-cells was determined in T-PLL patients (n = 109) and healthy donors (n =
14). In A-B the median ± interquartile range is shown. c CCR7 expression in pan T-cells or specific CCR7-expressing T-cell subsets (TN, TCM) from a
representative patient and a healthy donor. The expression pattern and intensity of CCR7 is shown. d T-PLL cells migrate towards CCR7 ligands.
Chemotaxis assays with T-PLL cells (n = 5) were performed with different doses of CCL19 and CCL21 (x axis). Each symbol represents the
percentage of migrated cells in each experimental condition relative to the number of cells loaded in the upper chamber (% input). The mean ±
SEM is shown. e CCR7 surface expression on T-PLL cells is associated with OS. The surface expression (% positive cells) of CCR7 was assessed by
flow cytometry in T-PLL patients with clinical follow-up data (n = 96). At diagnosis, cases were classified as CCR7 positive (> 20% CCR7+ T-PLL
cells) or negative (< 20%). OS was estimated and compared by Kaplan–Meier curves and log-rank test, respectively. The p-value of the log-rank
statistical test is given. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant
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of chemokines receptors in T-PLL, we studied in more
detail the operational CCR7-downstream pathways and
the mechanisms of action (MOA) mediated by a block-
ing anti-CCR7 mAb on primary T-PLL cells. This
characterization included analyses of the activity dis-
played by the Fab region (which can block the target/lig-
and interaction) and by the Fc region, which can engage
the immune cells or proteins, thus promoting effector
activities.
First, we explored MEK/ERK1/2, PI3K/AKT, and Rho/
ROCK/MLC as the main CCR7 signaling cascades [23]
to be inducible in primary T-PLL cells upon ligand bind-
ing. In 6 samples tested, both ligands induced ERK1/2,
AKT, and MLC phosphorylation, which peaked after 1,
2, and 5 min, respectively (Fig. 2 a). Additionally, we
confirmed that activation of these cascades was blocked
by an anti-CCR7 mAb.
CCR7 mediates T-PLL cell migration and invasion, which
are neutralized by CCR7 mAbs
As CCR7 mediated T-PLL cell chemotaxis (Fig. 1d), we
postulated that neutralizing this process could prevent
leukemic dissemination to CCL19/CCL21 producing lo-
cations (SLO and CNS). As a proof-of-concept, anti-
CCR7 mAb blocked in vitro migration of primary T-PLL
cells towards CCL19/CCL21 in uncoated transwell
chambers (Fig. 2b). The mAb also abrogated cell pro-
cesses necessary for the migratory response [33] such as
actin-skeleton reorganization (Supplementary Figure 3-
A-B) or the development of uropods (Supplementary
Figure 3-C-D). Furthermore, we performed chemokine-
induced invasion assays in transwell chambers coated
with Matrigel (Fig. 2c). Compared to basal invasion, both
ligands increased the number of invading cells (albeit
CCL19-mediated invasion seemed stronger) and such in-
vasion was almost completely inhibited by the anti-
CCR7 mAb.
Through TEM assays we also confirmed that T-PLL
cells efficiently migrated across endothelium (HUVEC
monolayers) in response to CCL19/CCL21 (Fig. 2d). In
these experiments, CCL21 outperformed CCL19 prob-
ably due to the ability of CCL21 to bind endothelium
through its C-terminal tail [34]. Again, the anti-CCR7
mAb completely blocked migration towards both che-
mokines (Fig. 2d). Release of the gelatinases MMP-2 and
-9 by tumor cells degrades matrices and/or basement
membrane, which is a key step in invasion/metastasis.
To assess whether these enzymes are regulated by CCR7
ligation, T-PLL cells were incubated with/without che-
mokines and cell media were then analyzed by gelatin
zymography. Figure 2e shows that tumor cells constitu-
tively secreted activated MMP-9 with no traces of acti-
vated MMP-2. Although CCL19/CCL21 promoted
differential invasion across Matrigel™ or HUVEC
(Fig. 2c.d), both chemokines significantly increased the
secretion of MMP-9 in zymographies to a similar extent,
which was in turn blocked by exposure to anti-CCR7
mAbs (Fig. 2 e).
T-PLL cell survival, promoted by CCR7 ligands, is impaired
by anti-CCR7 mAbs
CCR7 promotes cell survival and proliferation in differ-
ent hematological malignancies [23, 35]. Here, exposure
of T-PLL cells to either CCL19 or CCL21 induced a
moderate but significant increase of viability in long-
term suspension cultures (Fig. 2f) without affecting pro-
liferation (Fig. 2 g). This proactive impact on cell viabil-
ity was abrogated by the anti-CCR7 mAb, which likely
promoted cell death by blocking these CCR7-mediated
pro-survival signals because this antibody did not medi-
ate direct cell death upon target binding in the absence
of these chemokines (Fig. 2h).
Table 2 Cox regression analyses
HR p-value 95% CI n° cases LR Chi2 Prob > Chi2
% CCR7
(continuous)
1.004 0.235 0.997–1.013 92 1.52 0.217
% CCR7
(high/low)
2.426 0.044 1.026–5.739 93 5.08 0.024
% CCR7 within the CCR7-high group (continuous) 0.988 0.092 0.973–1.002 80 2.43 0.119
Abbreviations: CI Confidence interval, HR Hazard ratio, LR Likelihood ratio; high: ≥20% positive T-PLL cells by flow cytometry; low: < 20% positive T-PLL cells by
flow cytometry
Table 1 CD45RO/RA pattern of CCR7-negative vs CCR7-positive







Naïve CD45RO−CD45RA+ 0 3
Pan-memory CD45RO−CD45RA− 0 2
Transition CD45RA+/RO+ 3 16
Central or effector memory
CD45RA−/RO+
6 43
Median age and range (years) 68 [32–81]
Fisher’s exact test (p = 0.86)
Pearson’s Chi-squared test (p =
0.82).
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Anti-CCR7 mAb triggers a strong CDC activity against T-
PLL cells
Therapeutic mAbs can induce target cell death through
Fc-mediated cytotoxicity, including CDC and ADCC. In
this study, the anti-CCR7 mAb triggered a strong in vitro
CDC activity against T-PLL cells obtained from 8 patients
not treated before with alemtuzumab (Fig. 3 a). This was
observed at concentrations as low as 0.125 μg/mL. Simi-
larly, alemtuzumab mediated a significant CDC but was
outperformed by anti-CCR7 mAb at dose ranges of
0.125–5 μg/mL. Anti-CCR7 exposure was also highly ef-
fective against cells from four alemtuzumab-relapsed/re-
fractory (R/R) patients (Fig. 3 b) and against cells from SS
patients (Supplementary Figure 4).
The differences in CDC observed between alemtuzu-
mab and the anti-CCR7 mAb can be attributed to a dif-
ferent isotype (human IgG1 vs mouse IgG2a), but also to
different target surface expression levels. Compared with
CD52, which is highly expressed on T-prolymphocytes
[36], CCR7 levels were slightly higher in T-PLL cells
from treatment naïve patients (Fig. 3 c,d,e). Accordingly,
significantly diminished levels of CD52 where seen in
three out of four R/R patients while the other lacked the
target (Fig. 3 c,d,e). In R/R patients a non-significant re-
duction of CCR7 expression was also observed. Despite
this, CCR7 expression levels were enough to mediate
CDC upon anti-CCR7 treatment, while alemtuzumab-
mediated CDC was abolished (Fig. 3b).
Another receptor targeted in T-cell malignancies is
CCR4. In both naïve and alemtuzumab-R/R patients,
expression of CCR4 was much lower than CD52 and
CCR7 (Fig. 3 c,d,e) thus suggesting that anti-CCR4 anti-
bodies, such as mogamulizumab, are not suitable for
treating T-PLL. As seen with CCR7 and CD52, CCR4
expression was also decreased in R/R patients, thus indi-
cating that down-regulation of surface markers is a com-
mon event in such population.
Finally, anti-CCR7 mAb did not trigger ADCC of T-
PLL cells mediated by the recruitment of effector mono-
nuclear myeloid cells (data not shown) or NK cells iso-
lated from human PB (Fig. 3f) or from mouse spleens
(Fig. 3 g), suggesting that anti-CCR7 mAb was ineffect-
ive in activating the FcγR on immune cells.
Antibody-based CCR7 targeting is effective in novel
xenograft models of T-PLL
To further evaluate the utility of anti-CCR7 therapy in
T-PLL we conducted in vivo proof-of-concept tests.
Since the mAb did not recognize murine CCR7, we per-
formed these studies in novel systemic xenogeneic
models developed in host immunodeficient mice by
intravenous injection of the SUP-T11 T-cell leukemia
line [37], which, at the molecular level, resembles T-PLL
as close as possible [38]. In these models, the tumor
spread through PB, lymphoid organs (LN, spleen, and
BM) and non-lymphoid tissues (liver, lung, and brain)
(Supplementary Figure 5). Despite the fact that some
characteristic surface markers of T-PLL were absent in
SUP-T11 cells (e.g. CD4, CD8, CD25 and CD52), SUP-
T11 was selected based on laboratory findings
(See figure on previous page.)
Fig. 2 Blocking CCR7 neutralizes target-mediated cell functions on T-PLL. a Anti-CCR7 mAb blocks CCR7 activation and signal transduction in T-
PLL cells. Serum-starved T-PLL cells were pre-treated with 10 μg/mL of anti-CCR7 or the respective IC for 30 min and then treated with CCL19 or
CCL21 for different time points. Cell extracts were analyzed by Western blot. The figure shows representative blots from 6 independent
experiments. b Anti-CCR7 mAb neutralizes CCR7-mediated T-PLL cells migration in response to CCL19 and CCL21. Chemotaxis of T-PLL cells
induced by CCL19 and CCL21 was assayed in uncoated transwell chambers for 4 h. When indicated, cells were pre-treated with 10 μg/mL of anti-
CCR7 mAb or the respective IC (n = 6). c Blocking CCR7 abrogates T-PLL cells invasion driven by CCL19 and CCL21. T-PLL cells with or without
previous incubation with anti-CCR7 mAb or the matching IC were embedded in Matrigel™ before exposure to chemokines for 24 h. Values
represent the percentage of migrated cells referred to the total cells added (n = 4). d Anti-CCR7 mAb inhibits target-mediated T-PLL cells
migration across endothelium. T-PLL cells were incubated on the upper chamber of transwell filters coated with TNFα-activated HUVEC, in the
presence or absence of the indicated mAbs. Then chemokines were added and after 4 h, the cells were counted by flow cytometry. Values
represent the percentage of migrated cells referred to the total cells added (n = 4). e Anti-CCR7 mAb reduces target-mediated MMP-9 secretion.
CCR7 engagement up-regulates MMP-9 in T-PLL cells. Leukemic cells from 3 different patients (P1, P2 and P3) were pre-treated with anti-CCR7
mAb or an IC (10 μg/mL) and then incubated with/without CCL19 or CCL21 (1 μg/mL) for 24 h. The concentrated conditioned media were
analyzed by gelatin zymography to detect MMP-2 and MMP-9 secretion. MMP-9 was identified as the 92-kDa proactive form. Cell pellets of each
point were lysed and cell extracts were used to detect actin by Western blotting as loading control (C, fetal bovine serum (FBS) used as positive
control showing the degradation bands of active MMP-9 and MMP2). The average quantification of MMP-9 secretion (arbitrary units) for the 3
samples studied is given; basal levels of MMP-9 on bovine serum albumin (BSA) and without chemokines were normalized to 1. f Anti-CCR7 mAb
affects target-induced pro-survival signaling pathways. CCR7 ligands increase T-PLL cells survival, a process blocked by anti-CCR7 mAb. Cells from
4 patients were incubated in 1% FBS medium alone or with CCR7 ligands (1 μg/mL) for 72 h. Where indicated, cells were also incubated in the
presence of 10 μg/mL of anti-CCR7 mAb or an IC. The percentage of viable 7-AAD− Annexin-V− cells at 72 h is shown. g CCR7 ligands do not
induce proliferation of T-PLL cells. T-PLL cells (n = 5) were harvested and stained with CellTrace™ Violet reagent. Then, 5 × 105 cells were cultured
with 1% FBS complete medium alone or supplemented with CCL19 or CCL21. Every 24 h the successive generations of live cells were analyzed. h
Anti-CCR7 mAb does not induce direct apoptosis on T-PLL cells. Leukemic cells were incubated with anti-CCR7 (10 μg/ml) or the corresponding
IC in complete medium with 10% FBS (n = 5). Every 24 h the effect of the antibody was studied by Annexin-V/7-AAD double staining. In B, C, D,
E, F, G, H, bars (or symbols) represent mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant
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demonstrating a close resemblance with T-PLL regard-
ing CCR7 (Fig. 4 a) and based on the presence of the T-
PLL signature lesion of t (14;14)(q11;q13.2), an alteration
found in other mature T-cell leukemia [39, 40], but ex-
tremely rare in immature stages [1, 41]. Here, we con-
firmed this translocation (and the resulting TCL1
protein overexpression) and, in addition, the strong posi-
tivity for CD7 and CD26 (another characteristic markers
of T-PLL) [1], and the post-thymic, mature TCRαβ+
naïve phenotype characterized by intense expression of
CCR7 and CD45RA, and negativity for CD34, CD10,
TdT, CD117, HLA-DR, and the cortical thymic marker
CD1a (Supplementary Figure 6). Finally, we determined
that SUP-T11 cells migrated towards CCR7 ligands
in vitro (Fig. 4 b) and confirmed that the anti-CCR7
mAb was effective in blocking such migration and in in-
ducing CDC on SUP-T11 cells (Fig. 4 b,c).
To evaluate the in vivo anti-tumor efficacy of the anti-
CCR7 mAb, first we used as hosts the RAG2−/−γc−/−
strain, which lacks T, B, and functional NK cells, but has
complement activity [42], thus allowing in vivo testing of
the MOA characterized in vitro. To better represent a
clinical scenario for an anti-CCR7 treatment, we used a
post-implantation set-up in which tumor cells had mi-
grated to their target organs and niches (Fig. 4d). Ac-
cordingly, treatment was initiated 3 weeks after
intravenous inoculation of SUP-T11 cells, once they
were found in the BM (data not shown). Then, two
groups (n = 4) were treated with either 200 μg/mouse (~
10mg/kg) of anti-CCR7 mAb or IC twice on weeks 3–5
and once on weeks 7–9. In this model, anti-CCR7 mAb
significantly increased OS (Fig. 4e). While the survival
rate in the IC group was 0% (median survival of 86.5
days), all mice treated with the anti-CCR7 mAb
remained alive at the time when the last mouse in the
control group had to be euthanized. Animals treated
with the anti-CCR7 mAb did not develop clinical signs,
gained weight and survived up to 127 days, the time
when the animals were sacrificed which was considered
as a bona fide disease-free period. Accordingly, no pres-
ence of SUP-T11 cells was detected in PB (Fig. 4f)
whereas PB infiltration of control animals increased over
the time. At the time of sacrifice, no SUP-T11 cells were
seen in lymphoid and non-lymphoid tissues from anti-
CCR7 treated animals. Conversely, there was consistent
infiltration of these tissues in the control group (Fig. 4 g,
h).
In vivo anti-tumor activity of targeting CCR7 relies on
both fab- and fc-mediated action
The potential of the anti-CCR7 antibody was further
studied in irradiated NSG mice that besides lacking T, B,
and NK cells, also lack complement activation [42].
These settings were used to examine the therapeutic
benefit of blocking CCR7 by the Fab region, excluding
Fc-mediated cytotoxicities. Of note, the anti-CCR7 mAb
did not trigger in vitro FcγR-mediated activities on ef-
fector cells (Fig. 3 f,g) and irradiation provided a com-
plementary way to abrogate activation of myeloid
subsets. In this NSG model, we repeated the treatment
schedule used in RAG2−/−γc−/− mice (Fig. 4d). In the
model the median OS in controls was 110.5 days, com-
pared to 160 days in anti-CCR7 treated mice, and 50% of
anti-CCR7 treated mice were alive when the last control
mouse was euthanized (Fig. 4 i). Nonetheless, log-rank
tests showed no statistical differences between the sur-
vival curves of both groups, and anti-CCR7 therapy did
not significantly influence the presence of tumor cells in
the tissues (Fig. 4j). Together, these results indicate that
in anti-CCR7 mAb-based therapy both Fc- and Fab-
mediated activities are necessary to achieve the max-
imum therapeutic benefit in T-PLL.
Preventive anti-CCR7 mAb treatment tends to delay
tumor onset and to reduce tumor burden in the T-PLL
model
CCR7 plays critical roles in enabling tumor cells acces-
sing and establishing tumor microenvironments (TME),
(See figure on previous page.)
Fig. 3 Anti-CCR7 mAb mediates a strong CDC on T-PLL cells. a CDC on alemtuzumab-naïve patients. Leukemic cells from T-PLL patients (n= 8) were
incubated with anti-CCR7, anti-CD52 (alemtuzumab), or an IC at the indicated concentrations and then exposed to rabbit complement for 1.5 h. The
percentage of specific cell lysis was determined through quantification of 7-AAD incorporation by flow cytometry. b CDC on alemtuzumab-refractory
patients. Specific lysis on T-PLL cells from 4 refractory patients was assayed as described in A. c Relative median fluorescence intensity (RMFI) of CCR7, CD52
and CCR4 in T-PLL cells from alemtuzumab-naïve or alemtuzumab-refractory patients (R/R). Cells obtained from PB samples of patients not treated with
alemtuzumab (n = 8; black bars) or refractory to this mAb (n= 4; grey bars) were analyzed by flow cytometry to determine CCR7, CD52, and CCR4 surface
density measured as MFI relative to a corresponding IC. d CCR7, CD52, and CCR4 surface expression in T-PLL cells from one representative alemtuzumab-
naïve or -refractory patient. E) Proportion of CCR7+, CD52+ and CCR4+ in T-PLL cells from alemtuzumab-naïve or alemtuzumab–refractory patients. The
percentage of positive cells was determined in naïve (n = 8; black bars) and refractory patients (n = 4; grey bars). f and g Anti-CCR7 antibody does not
mediate antibody-dependent cell-mediated cytotoxicity (ADCC). T-PLL cells were incubated with media alone or in the presence of an IC, anti-CD52
(alemtuzumab) or anti-CCR7 antibodies. f Isolated and IL-2-stimulated human NK cells from a healthy donor were used as effector cells at an effector to
target (E:T) ratio of 6:1 (n= 1). g Isolated and IL-2-stimulated wild-type mouse NK cells from spleen (n= 2) were used as effector cells at an effector to target
(E:T) ratio of 6:1. After 4 h, the percentage of T-PLL cells killed by ADCC was determined through 7-AAD staining by flow cytometry. In A, B, C, E, F, and G, bars
(or symbols) represent mean± SEM. *, p< 0.05; **, p< 0.01; ***, p< 0.001; ns, not significant
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e.g. shown in syngeneic models of Burkitt lymphoma
[43] where genetic deletion of CCR7 delayed arrival at
such milieus and niche formation, and impaired cross-
talk between malignant and accessory cells [43]. Based
on this, we aimed to study whether ‘preventive’
administration of anti-CCR7 mAb could impact disease
establishment. To trace engraftment of tumor cells, we
developed a new bioluminescent model in which SUP-
T11 cells, stably expressing luciferase, were intraven-
ously injected into NSG mice. Expression of CCR7 on
Fig. 4 Anti-CCR7 is effective as a monotherapy in a novel post-implantation disease model of T-PLL. a SUP-T11 cells show similar CCR7 expression
pattern than T-PLL patients. Tumor cells from one representative patient (Px) and from SUP-T11 cell line were stained with anti-CCR7 mAb, anti-CD52
mAb and an irrelevant IC. The graph shows frequency histograms with the pattern and intensity of each surface marker. b Anti-CCR7 mAb blocks
migration of SUP-T11 cells. Chemotaxis of SUP-T11 cells induced by CCL19 and CCL21 (1 μg/mL) was assayed in uncoated transwell chambers (n = 3).
Where indicated, cells were pre-treated with 10 μg/mL of anti-CCR7 or the respective isotype control, IC. Bars represent mean ± SEM. c Anti-CCR7
mediates CDC on SUP-T11 cells. Cells were incubated with anti-CCR7, anti-CD52 (alemtuzumab) or an IC at the indicated concentrations and then
exposed to rabbit complement for 1.5 h (n = 2). Each symbol represents mean ± SD. d Schematic representation of model development and treatment
schedule. The novel T-PLL-like systemic model was developed by intravenous inoculation of 5 × 105 SUP-T11 cells into RAG2−/−γc−/− deficient mice.
On day 21 (*), when SUP-T11 cells were detected in bone marrow (BM), animals were randomized (n = 4 animals/group). Mice were treated
intraperitoneally with 10mg/kg (~ 200 μg/mouse) of anti-CCR7 mAb or its respective IC twice in weeks 3, 4, 5 and once in weeks 7, 8, 9 (arrows
indicate antibody treatment days). e Anti-CCR7 mAb therapy increases survival of SUP-T11-xenografted mice. Survival was estimated and compared by
Kaplan-Meier survival curves and log-rank test, respectively. f Anti-CCR7 mAb therapy reduces tumor burden in PB. The percentage of SUP-T11 cells in
PB was determined by flow cytometry all over the experiment. Each point represents mean ± SD. g and h Anti-CCR7 mAb therapy impairs infiltration
of lymphoid and non-lymphoid organs. g At sacrifice, one million cells from spleen, BM, PB, lung, liver, and brain were harvested and incubated with
anti-hCD5 and anti-hCD45 antibodies. The percentage of SUP-T11 cells observed in each tissue is shown. Each symbol represents one individual
mouse. Horizontal bars represent mean percentage of SUP-T11 cells of each group. h Immunohistochemistry (IHC) analyses were performed in tissue
sections from spleen, liver, brain, and lungs using anti-hCD45 mAb. Representative pictures from both a control mouse and an anti-CCR7 treated
mouse are shown. i and j Anti-CCR7 Fab-mediated MOA are insufficient to achieve the maximal therapeutic response. The novel TPLL-like systemic
model was developed by intravenous inoculation of 5 × 105 SUP-T11 cells into irradiated NSG deficient mice (see picture d). On day 21, and mimicking
model on RAG2−/−γc−/−, animals were randomized (n = 4 animals/group). Mice were treated intraperitoneally with 10mg/kg (~ 200 μg/mouse) of anti-
CCR7 mAb or its respective IC twice in weeks 3, 4, 5 and once in weeks 7, 8, 9 (arrows indicate antibody treatment days). i Fab-mediated MOA in anti-
CCR7 therapy induce a non-significant increase in survival. j Fab-mediated MOA in anti-CCR7 therapy do not reduce tumor cell infiltration. At sacrifice,
flow cytometry analysis was performed as disclosed in g. Each symbol represents one individual mouse. Horizontal bars represent mean percentage of
SUP-T11 cells of each group. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant
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these SUP-T11-luc+ cells was identical to their parental
cells (data not shown). Two groups of 4 animals each
were treated with either a single dose of 100 μg/mouse
(~ 5mg/kg) of the anti-CCR7 mAb or IC 2 h before
intravenous inoculation of SUP-T11-luc+ cells (Fig. 5a).
Bioluminescence images were obtained every 2 weeks
until week 10. Notably, single-dose anti-CCR7 treatment
seemed to delay disease onset to week 8 (as determined
by the first appearance of bioluminescent signals) and
also tended to modestly reduce tumor burden, although
no statistical differences were found between groups
(Fig. 5 b,c). Similarly, post-mortem analysis demon-
strated that this ‘preventive’ treatment had a mild
though non-significant impact on the cell viability (spe-
cifically in LN) and proliferation (in LN and other tumor
niches like spleen or brain) of SUP-T11-luc+ cells (Fig. 5
d). Together, these results suggest that CCR7 might act
as a key player in niche colonization and formation by
SUP-T11 cells and advance a potential role of anti-
CCR7 therapy in impairing the formation of pro-
tumorous sanctuaries in T-PLL, such as LN or brain, by
reducing migration to tumor niches, and, in addition, by
affecting survival and proliferation of tumor cells within
these locations.
Discussion
T-PLL is an aggressive disease with a poor prognosis.
Despite allo-HSCT is given under curative intent, disease
control for more than 5 years is documented in a minor
fraction of patients [1, 17]. Therefore, curative therapies
are not available for the majority of cases. In this work,
we show that CCR7 is highly expressed on T-PLL cells
and that this expression has a negative impact on patient
survival. Indeed, in our cohort, CCR7 expression was
found in 83 out of 96 cases (~ 86.5%) and patients lack-
ing CCR7 (13.5%) tended to have a better overall prog-
nosis. Nonetheless, our results on CCR7 expression also
confirm that T-PLL is a very complex and heteroge-
neous disease, therefore, further confirmation of the im-
pact of CCR7 in short T-PLL patient survival is needed
with standardized flow cytometry protocols in larger co-
horts. Even though, this is the first time that such a cor-
relation is presented in blood cancers that makes CCR7
a reasonable therapeutic target in T-PLL.
Our results also suggest that CCR7 is overexpressed in
T-PLL when compared to pan-T cells obtained from
HD and that expression in T-PLL certainly resembles a
transition in the differentiation stages of T-cells, with a
vast majority of patients showing CCR7 expression simi-
lar to that found in TN and TCM phenotypes. When ana-
lyzing these data in the context of an anti-CCR7
therapeutic approach, we could show that (i) a relevant
proportion of T-PLL patients would potentially be
amenable to this treatment as they strongly express
CCR7 and (ii) that one could potentially expect a limited
hematologic toxicity since not all normal T-cell subsets
of the patient would be targeted (e.g. pathogen-specific
CCR7− effector cells).
In addition, we demonstrate CCR7 functionality in the
spread of T-PLL. CCR7 is shown to trigger migration
and invasion of T-PLL cells and to facilitate an invasive
phenotype by promoting the secretion of MMP-9. Our
data also suggest that CCR7 enables access of T-PLL T-
cells to lymphoid and non-lymphoid organs thus con-
firming the role of CCR7 guiding hematogenous and
lymphatic spread of malignant cells [19, 21, 29, 44–46].
In these localizations, and more specifically in the LN,
CCR7 may mediate survival of T-PLL cells upon CCR7
ligand engagement, as suggested by our in vitro and
in vivo studies. Accordingly, stromal cells in the LN may
confer resistance to spontaneous apoptosis by secreting
CCL19 and IL-7 [47]. In addition, CCR7 may mediate
proliferative cues on T-PLL cells. Although we do not
show a direct impact of CCR7 blockade on in vitro pro-
liferation, we cannot exclude that leukemic cells guided
via CCR7-ligand based chemotaxis to protective niches
(e.g. brain, spleen and LN) could find other proliferative
stimuli such as soluble factors or other cell types, includ-
ing dendritic cells or stromal cells [21, 22, 43, 48]. In-
deed, we show that targeting CCR7 has an impact on
proliferating Ki67+ tumor cells in vivo.
In T-PLL, alemtuzumab responses are transient and
disease progression and acquisition of resistance are in-
evitable [1]. Therefore, alternative treatment strategies
are urgently needed. In this work we also evaluated
mAb-based anti-CCR7 therapy as a novel tool of treat-
ment in this disease. Our findings support a double
mechanism of action of this type of antibodies consisting
in the combination of cell killing and blocking of cell
spread and niche homing (Supplementary Figure 7).
Anti-CCR7 mAbs killed leukemic cells derived from
both untreated and alemtuzumab-refractory patients
through host effector mechanisms, specifically CDC.
Also, the anti-CCR7 mAb used in this study has an add-
itional mechanism to induce T-PLL cell death, namely
by blocking the interaction of CCR7 with its ligands and
thus disrupting pro-survival pathways. We did not spe-
cifically study which signaling molecules are involved in
this process, however, blocking CCR7 abrogated PI3K
and ERK activation, two important components of
CCR7-mediated pro-survival pathways in hematological
malignancies [23, 35] that have shown to be relevant in
T-PLL pathogenesis [49, 50]. In T-PLL, disease distribu-
tion is an important factor determining outcome. For
example, the proportion of cases that respond to alemtu-
zumab is low in patients with CNS disease [1] and/or
bulky LN masses [8, 51]. In this regard, anti-CCR7
showed here to be effective in eradicating tumor cells
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from several localizations, including LN and CNS. Anti-
CCR7 therapy also inhibited secretion of MMP-9 and
blocked T-PLL cell invasion in matrices and through
endothelia. Targeting these processes is important to
block lymphatic and distant dissemination of tumor cells
as inferred from several clinical studies on T-cell lymph-
omas, chronic lymphocytic leukemia, or solid tumors
[19, 24, 29, 46, 52]. Indeed, it is worth highlighting that
multiple prominent high endothelial veins (HEV) are
often infiltrated by neoplastic cells in T-PLL [53], which
suggests CCL21 as a major route for homing into
lymphoid tissues and mediating the dissemination of T-
PLL cells to different organs. Accordingly, results ob-
tained from our novel in vivo models of T-PLL confirm
that blocking CCR7 might be a relevant way to impair
homing of leukemic T-cells to protective niches. Con-
sistent with this action, anti-CCR7 mAbs tended to delay
disease onset, most likely by the inhibition of CCR7-
guided niche occupation. Similarly, Rhem et al demon-
strated that engraftment of CCR7-deficient lymphoma
B-cells was associated with a significant delay in the ap-
pearance of disease [43].
Overall, our results envision anti-CCR7 mAbs as a
promising therapeutic application for T-PLL, a disease
where antibodies were not included in recent searches
for novel promising drugs. Particularly, anti-CCR7 mAbs
could be beneficial in the context of alemtuzumab-
relapsed/refractory disease or in patients with low-level
CD52 expression [8, 36] or lack of CD52 [54, 55]. Ac-
cording to our data, anti-CCR7 therapy could also target
Fig. 5 Anti-CCR7 Fab-mediated MOA moderately delay tumor onset and inhibit tumor burden in the SUP-T11-luc+ disseminated T-PLL models. a
Schematic representation of development and treatment schedule in model 1. This preventive model was developed by treating irradiated NSG
deficient mice with a single dose of 5 mg/kg (~ 100 μg/mouse) of either anti-CCR7 (n = 4) or the respective IC (n = 4) 2 h before the intravenous
inoculation of 5 × 105 SUP-T11-luc+ cells (arrow indicates antibody administration). b-c Anti-CCR7 mAb preventive therapy tends to reduce tumor
burden and growth. Tumor burden follow-up was determined by whole body (back and front) bioluminescent analyses of each mouse on weeks
4, 6, 8, and 10. To simplify, only front images are shown (b). Quantification of luciferase activity is shown as mean ± SEM (c). d Blocking CCR7
seems to induce cell death in the LN and to reduce the proliferative phenotype in SUP-T11-luc+ cells migrated to the LN, spleen and brain. At
sacrifice, one million cells from LN, spleen, and brain were harvested for flow cytometry analyses. Cells were incubated with anti-human-CD5 and
anti-hCD45 antibodies, and with either Annexin-V/7-AAD, to quantitatively determine the proportion of non-viable cells, or with fluorochrome-
conjugated antibody directed against the proliferative protein Ki67 in order to determine expression levels of this marker. The percentage of SUP-
T11-luc+ dead cells and the median intensity of fluorescence of Ki67 relative to the IC (RMFI, arbitrary units) are shown. Each symbol represents
one individual mouse. Horizontal bars represent the mean. ns, not significant
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or avoid CNS infiltration, tackle bulky lymphadenopathies,
or prevent T-PLL relapse in settings of minimal residual
disease in lymphoid organs or other sites where alemtuzu-
mab is ineffective in tumor cell clearance. To this end,
anti-CCR7 mAbs could be used in monotherapy or com-
bined with alemtuzumab, with purine analogs, or with
novel small-molecule inhibitors that are under develop-
ment and that target other, potentially synergistically act-
ing pathways [56–59]. Finally, targeting CCR7 with mAbs
may fulfill not only the urgent need for more rationally
based therapies in T-PLL, but also in many other CCR7-
expressing T-cell malignancies such as SS/MF [20, 60], T-
ALL [21, 22], and ATLL [19, 61], in which particularly ag-
gressive diseases characteristically express high levels of
CCR7 [19, 61] and where few standard mAb-based treat-
ment strategies have been developed so far.
Conclusions
In this report, we have described for the first time the
role of CCR7 in T-PLL. The activity of this receptor as-
sociates to clinical outcome and contributes to a wide-
spread dissemination of the disease to specific niches
where leukemic cells find proliferative and survival cues.
Moreover, our results on the activity of an anti-CCR7
mAb, both in vitro and in vivo confirm CCR7 as an at-
tractive molecule for novel mAb-based therapeutic ap-
plications in T-PLL, a disease where recent drug screen
efforts and studies addressing new compounds have fo-
cused on chemotherapy or small molecules.
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